Moderna Inc. has announced that the U.S. Food and Drug Administration (FDA) has approved their RSV vaccine, mRESVIA® (mRNA-1345), for adults aged 18-59 who are at increased risk for respiratory syncytial virus (RSV) disease. This expands the vaccine's previous approval for adults aged 60 and older, granted in May 2024. The approval is based on results from Moderna's Phase 3 study, which showed the vaccine to be well-tolerated and effective in generating immune responses in the younger at-risk population. Moderna plans to have mRESVIA available for both younger and older adults in the U.S. for the 2025-2026 respiratory virus season.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.